Research progress on antibody-drug conjugates in targeted therapy of lung cancer
Lung cancer is a leading cause of cancer-related mortality in China,commanding increasing attention.The prevailing therapeutic strategies rely on chemotherapy,targeted therapy and immunotherapy.However,the emergence of drug resistance and disease progression are inevitable challenges in clinical practice,underscoring an imperative for the development of more efficacious strategies to enhance patient prognoses.Antibody-drug conjugate(ADC),as an innovative anti-tumor therapy,is composed of three key elements:monoclonal antibodies that specifically target tumor cells,highly cytotoxic drug payload,and linker that connect these two components.By binding the specific antibodies to antigens on the surface of tumor cells,ADC deliver the cytotoxic payload directly to the tumor cells,thus overcoming the limitations of traditional chemotherapy and monoclonal antibody therapies.This article provides a comprehensive review of the latest research advancements of ADC in the field of lung cancer treatment,discussing their therapeutic-potential in terms of efficacy and safety,with the aim of offering a reference for the clinical management of lung cancer.
万方数据
维普
